These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 21116626

  • 21. [An update of the surgical indications for gastrointestinal stromal tumors].
    Bonvalot S.
    J Chir (Paris); 2008; 145 Suppl 3():6S8-11. PubMed ID: 19060842
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Downstaging of a gastric GIST by neoadjuvant imatinib and endoscopic assisted laparoscopic resection.
    Cavaliere D, Vagliasindi A, Mura G, Framarini M, Giorgetti G, Solfrini G, Tauceri F, Padovani F, Milandri C, Dubini A, Ridolfi L, Ricci E, Verdecchia GM.
    Eur J Surg Oncol; 2007 Oct; 33(8):1044-6. PubMed ID: 17467951
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A, den Bakker MA, van Geel AN, Eggermont AM, Sleijfer S, Verweij J, de Wilt JH, Verhoef C.
    Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
    [Abstract] [Full Text] [Related]

  • 31. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
    Liegl B, Hornick JL, Antonescu CR, Corless CL, Fletcher CD.
    Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
    [Abstract] [Full Text] [Related]

  • 32. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
    Rutkowski P, Debiec-Rychter M, Nowecki ZI, Wozniak A, Michej W, Limon J, Siedlecki JA, Jerzak Vel Dobosz A, Grzesiakowska U, Nasierowska-Guttmejer A, Sygut J, Nyckowski P, Krawczyk M, Ruka W.
    Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
    [Abstract] [Full Text] [Related]

  • 33. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors.
    Gold JS, van der Zwan SM, Gönen M, Maki RG, Singer S, Brennan MF, Antonescu CR, De Matteo RP.
    Ann Surg Oncol; 2007 Jan; 14(1):134-42. PubMed ID: 17080234
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Expert consensus on surgical treatment for gastrointestinal stromal tumors].
    Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):947-8. PubMed ID: 18478940
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Neoadjuvant therapy for gastrointestinal stromal tumor (GIST): racing against resistance.
    Gold JS, Dematteo RP.
    Ann Surg Oncol; 2007 Apr; 14(4):1247-8. PubMed ID: 17265116
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.